OncoMatch/Clinical Trials/NCT03589729
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Is NCT03589729 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: Cladribine · Cytarabine · Dexrazoxane Hydrochloride · Gemtuzumab Ozogamicin · Idarubicin — This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy (hydroxyurea, cytarabine, azacytidine, decitabine, all-trans retinoic acid)
Prior therapy for any of the cohorts may include with hydroxyurea, rescue doses of cytarabine, various combination-chemotherapy regimens, hematopoietic growth factors, azacytidine, decitabine, ATRA (all-trans retinoic acid).
Lab requirements
Kidney function
Creatinine < 1.5 x ULN
Liver function
Bilirubin < 2mg/dL; AST and/or ALT < 3 x ULN (or < 5 x ULN if related to leukemic involvement); hyperbilirubinemia allowed if due to Gilbert's hyperbilirubinemia
Cardiac function
Baseline left ventricular ejection fraction (LVEF) >= 50% by echocardiography (echo) or multigated acquisition (MUGA) scan
Baseline left ventricular ejection fraction (LVEF) is greater than or equal to 50% by echocardiography (echo) or multigated acquisition (MUGA) scan. Bilirubin < 2mg/dL. AST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) < 3 x ULN (upper limit of normal) - or < 5 x ULN if related to leukemic involvement. Creatinine < 1.5 x ULN. Hyperbilirubinemia is allowed if due to Gilbert's hyperbilirubinemia.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03589729 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify